KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $11.1 million.

  • Adaptive Biotechnologies' Gains from Investment Securities fell 1087.91% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 1087.91%. This contributed to the annual value of $12.3 million for FY2024, which is 450.29% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Gains from Investment Securities stood at $11.1 million for Q3 2025, which was down 1087.91% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Gains from Investment Securities peaked at $156.5 million during Q4 2021, and registered a low of -$114000.0 during Q1 2024.
  • In the last 5 years, Adaptive Biotechnologies' Gains from Investment Securities had a median value of $12.8 million in 2021 and averaged $17.6 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Gains from Investment Securities surged by 7381666.0% in 2023 and then plummeted by 10077.11% in 2024.
  • Adaptive Biotechnologies' Gains from Investment Securities (Quarter) stood at $156.5 million in 2021, then crashed by 95.16% to $7.6 million in 2022, then tumbled by 79.35% to $1.6 million in 2023, then crashed by 77.44% to $353000.0 in 2024, then soared by 3033.38% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $11.4 million for Q2 2025, and $11.9 million during Q1 2025.